08:59 AM EDT, 10/15/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday its phase 2/3 Vibrance-MG study of nipocalimab in adolescents with generalized myasthenia gravis met its primary endpoint by achieving sustained disease control.

Treatment with nipocalimab plus standard of care reduced immunoglobulin G levels by 69% over 24 weeks, the company said. The combination treatment also showed showed improvement in disease activity scores, it added.

The treatment was well-tolerated with no serious adverse events, Johnson & Johnson ( JNJ ) said.

Price: 159.60, Change: -2.00, Percent Change: -1.24